NASDAQ:HZNP Horizon Therapeutics Public - HZNP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Horizon Therapeutics Public Limited Please log in to your account or sign up in order to add this asset to your watchlist. $109.17 +0.65 (+0.60%) (As of 03/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$108.63▼$109.2650-Day Range$107.32▼$113.2452-Week Range$57.84▼$117.49Volume1.70 million shsAverage Volume2.48 million shsMarket Capitalization$24.94 billionP/E Ratio48.96Dividend YieldN/APrice Target$111.42 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Horizon Therapeutics Public MarketRank™ ForecastAnalyst RatingHold2.27 Rating ScoreUpside/Downside2.1% Upside$111.42 Price TargetShort InterestHealthy1.77% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.54Based on 8 Articles This WeekInsider TradingSelling Shares$8.13 M Sold Last QuarterProj. Earnings Growth20.24%From $5.73 to $6.89 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.04 out of 5 starsMedical Sector470th out of 995 stocksPharmaceutical Preparations Industry218th out of 482 stocks 1.1 Analyst's Opinion Consensus RatingHorizon Therapeutics Public has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 3 buy ratings, 8 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $111.42, Horizon Therapeutics Public has a forecasted upside of 2.1% from its current price of $109.17.Amount of Analyst CoverageHorizon Therapeutics Public has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.77% of the outstanding shares of Horizon Therapeutics Public have been sold short.Short Interest Ratio / Days to CoverHorizon Therapeutics Public has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Horizon Therapeutics Public has recently increased by 23.93%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHorizon Therapeutics Public does not currently pay a dividend.Dividend GrowthHorizon Therapeutics Public does not have a long track record of dividend growth. Previous Next 3.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHorizon Therapeutics Public has received a 34.65% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Nonsteroidal anti-inflammatory drugs", "Pegloticase", "Cysteamine", "Sodium phenylbutyrate", and "Inebilizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Horizon Therapeutics Public is -2.61. Previous Next 2.0 News and Social Media Coverage News SentimentHorizon Therapeutics Public has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Horizon Therapeutics Public this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for HZNP on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Horizon Therapeutics Public to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Horizon Therapeutics Public insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,125,648.00 in company stock.Percentage Held by InsidersOnly 2.50% of the stock of Horizon Therapeutics Public is held by insiders.Percentage Held by Institutions91.01% of the stock of Horizon Therapeutics Public is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Horizon Therapeutics Public are expected to grow by 20.24% in the coming year, from $5.73 to $6.89 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Horizon Therapeutics Public is 48.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.16.Price to Earnings Ratio vs. SectorThe P/E ratio of Horizon Therapeutics Public is 48.96, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.62.Price to Earnings Growth RatioHorizon Therapeutics Public has a PEG Ratio of 3.79. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHorizon Therapeutics Public has a P/B Ratio of 4.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Horizon Therapeutics Public (NASDAQ:HZNP) StockHorizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.Read More Receive HZNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter. Email Address HZNP Stock News HeadlinesMarch 20, 2023 | americanbankingnews.comHorizon Therapeutics Public (NASDAQ:HZNP) Receives New Coverage from Analysts at StockNews.comMarch 17, 2023 | finance.yahoo.comHere's Why Horizon Therapeutics (HZNP) is a Strong Growth StockMarch 27, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 14, 2023 | finance.yahoo.comNew Analysis of MRI Findings Show UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)March 11, 2023 | fool.comHorizon Therapeutics Public (NASDAQ: HZNP)March 11, 2023 | finance.yahoo.com7 Over-$100 Stocks That Are Worth Every PennyMarch 3, 2023 | msn.comHere's How Much You Would Have Made Owning Horizon Therapeutics Stock In The Last 5 YearsMarch 1, 2023 | finance.yahoo.comHorizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial ResultsMarch 27, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!February 28, 2023 | finance.yahoo.comHorizon Therapeutics plc Opens Applications for #RAREis Global Advocate Grant ProgramFebruary 25, 2023 | markets.businessinsider.comHorizon's UPLIZNA Trials Show No Increase In COVID-19 Infection Susceptibility, Antibody DepletionFebruary 23, 2023 | finance.yahoo.comNew Data Suggest UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Did Not Increase the Risk of COVID-19 Infection or Reduce Antibody Levels From Childhood VaccinesFebruary 23, 2023 | finance.yahoo.comHorizon Therapeutics Public Limited Company (HZNP) Shares Got Re-Rated Due to Acquisition AnnouncementFebruary 16, 2023 | msn.comBillionaire George Soros' 7 Top Stock Picks in 2023February 15, 2023 | msn.comAmgen bond offering to help fund Horizon Therapeutics acquisitionJanuary 30, 2023 | finance.yahoo.comHorizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2022 Financial Results on March 1, 2023January 27, 2023 | finance.yahoo.comRule 15 (c) Announcement – Horizon Therapeutics plcJanuary 23, 2023 | finance.yahoo.comRule 17 (b) Announcement – Horizon Therapeutics plcJanuary 18, 2023 | finance.yahoo.comHorizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Primary Endpoint in Both Patient PopulationsJanuary 17, 2023 | finance.yahoo.comHere’s Why Horizon Therapeutics Public Limited Company (HZNP) Surged in Q4January 12, 2023 | finance.yahoo.comRule 2.12 Announcement – Horizon Therapeutics plcJanuary 4, 2023 | finance.yahoo.comHorizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus ErythematosusJanuary 3, 2023 | finance.yahoo.comRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)December 20, 2022 | finance.yahoo.comIf You Invested $1000 in Horizon Therapeutics a Decade Ago, This is How Much It'd Be Worth NowDecember 20, 2022 | finance.yahoo.comUPLIZNA® (inebilizumab-cdon) Approved in Brazil for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)December 13, 2022 | benzinga.comSTOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Horizon Therapeutics Public Limited Co. - HZNPDecember 13, 2022 | finance.yahoo.comForm 8.1 Opening Position Disclosure (Horizon Therapeutics plc)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HZNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter. Email Address HZNP Company Calendar Last Earnings3/01/2023Today3/27/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:HZNP CUSIP44047T10 CIK1492426 Webwww.horizontherapeutics.com Phone(531) 772-2100Fax224-383-3001Employees2,115Year Founded2008Price Target and Rating Average Stock Price Forecast$111.42 High Stock Price Forecast$144.00 Low Stock Price Forecast$71.00 Forecasted Upside/Downside+2.7%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$2.23 Trailing P/E Ratio48.66 Forward P/E Ratio18.94 P/E Growth3.79Net Income$521.48 million Net Margins14.37% Pretax Margin14.52% Return on Equity23.04% Return on Assets12.81% Debt Debt-to-Equity Ratio0.50 Current Ratio3.85 Quick Ratio3.67 Sales & Book Value Annual Sales$3.63 billion Price / Sales6.83 Cash Flow$7.06 per share Price / Cash Flow15.38 Book Value$22.38 per share Price / Book4.85Miscellaneous Outstanding Shares228,450,000Free Float222,737,000Market Cap$24.79 billion OptionableOptionable Beta1.15 Social Links Key ExecutivesTimothy P. WalbertChairman, President & Chief Executive OfficerAaron L. CoxChief Financial Officer & Executive Vice PresidentJeffrey W. ShermanChief Medical Officer & Executive Vice PresidentVikram KarnaniPresident-International, Medical Affairs & EVPMichael A. DesJardinExecutive VP-Technical Operations & QualityKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZZoetisNYSE:ZTSGenmab A/SNASDAQ:GMABAlnylam PharmaceuticalsNASDAQ:ALNYBeiGeneNASDAQ:BGNEView All CompetitorsInsiders & InstitutionsCrystalline Management Inc.Bought 45,000 shares on 3/13/2023Ownership: 0.020%Victory Capital Management Inc.Bought 10,448 shares on 3/10/2023Ownership: 0.071%Mather Group LLC.Bought 2,759 shares on 3/10/2023Ownership: 0.001%Rockefeller Capital Management L.P.Bought 99,791 shares on 3/6/2023Ownership: 0.045%Voya Investment Management LLCSold 277,198 shares on 2/28/2023Ownership: 0.182%View All Insider TransactionsView All Institutional Transactions HZNP Stock - Frequently Asked Questions Should I buy or sell Horizon Therapeutics Public stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares. View HZNP analyst ratings or view top-rated stocks. What is Horizon Therapeutics Public's stock price forecast for 2023? 11 analysts have issued 12 month price targets for Horizon Therapeutics Public's stock. Their HZNP share price forecasts range from $71.00 to $144.00. On average, they anticipate the company's stock price to reach $111.42 in the next twelve months. This suggests a possible upside of 2.7% from the stock's current price. View analysts price targets for HZNP or view top-rated stocks among Wall Street analysts. How have HZNP shares performed in 2023? Horizon Therapeutics Public's stock was trading at $113.80 at the beginning of 2023. Since then, HZNP shares have decreased by 4.6% and is now trading at $108.52. View the best growth stocks for 2023 here. When is Horizon Therapeutics Public's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our HZNP earnings forecast. How were Horizon Therapeutics Public's earnings last quarter? Horizon Therapeutics Public Limited (NASDAQ:HZNP) issued its quarterly earnings data on Wednesday, March, 1st. The biopharmaceutical company reported $1.21 earnings per share for the quarter, topping analysts' consensus estimates of $1.09 by $0.12. The biopharmaceutical company earned $942.03 million during the quarter, compared to analyst estimates of $922.95 million. Horizon Therapeutics Public had a net margin of 14.37% and a trailing twelve-month return on equity of 23.04%. Horizon Therapeutics Public's revenue was down 7.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.41 EPS. What ETFs hold Horizon Therapeutics Public's stock? ETFs with the largest weight of Horizon Therapeutics Public (NASDAQ:HZNP) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), First Trust Merger Arbitrage ETF (MARB), Vesper U.S. Large Cap Short-Term Reversal Strategy ETF (UTRN), Invesco Dynamic Pharmaceuticals ETF (PJP), VictoryShares Nasdaq Next 50 ETF (QQQN), ProShares Merger ETF (MRGR), Invesco Nasdaq Biotechnology ETF (IBBQ) and Goldman Sachs Hedge Industry VIP ETF (GVIP). What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO? 70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees. What other stocks do shareholders of Horizon Therapeutics Public own? Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL). What is Horizon Therapeutics Public's stock symbol? Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP." Who are Horizon Therapeutics Public's major shareholders? Horizon Therapeutics Public's stock is owned by a number of institutional and retail investors. Top institutional investors include Avoro Capital Advisors LLC (3.09%), T. Rowe Price Investment Management Inc. (1.79%), Geode Capital Management LLC (1.36%), Soros Fund Management LLC (1.26%), Norges Bank (0.97%) and Deutsche Bank AG (0.91%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Timothy P Walbert, Vikram Karnani and William F Daniel. View institutional ownership trends. How do I buy shares of Horizon Therapeutics Public? Shares of HZNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Horizon Therapeutics Public's stock price today? One share of HZNP stock can currently be purchased for approximately $108.52. How much money does Horizon Therapeutics Public make? Horizon Therapeutics Public (NASDAQ:HZNP) has a market capitalization of $24.79 billion and generates $3.63 billion in revenue each year. The biopharmaceutical company earns $521.48 million in net income (profit) each year or $2.23 on an earnings per share basis. How many employees does Horizon Therapeutics Public have? The company employs 2,115 workers across the globe. Does Horizon Therapeutics Public have any subsidiaries? The following companies are subsidiares of Horizon Therapeutics Public: Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Israel Holding Corp. Ltd, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Services LLC, Horizon Therapeutics Switzerland GmbH, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics, Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, Raptor Pharmaceuticals, River Vision Development Corp., Vidara Therapeutics, and Viela Bio Inc..Read More How can I contact Horizon Therapeutics Public? Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The official website for the company is www.horizontherapeutics.com. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at investor-relations@horizontherapeutics.com, or via fax at 224-383-3001. This page (NASDAQ:HZNP) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.